



Patient Information Sheet

Title of the study: COVID-19 pandemic impact on severe asthma patients care in Europe

You are being invited to take part in this study. The study is taking place in 17 countries in Europe. It is important you understand why the study is being carried out before taking part. Please read the following information carefully and you can discuss it with others if you wish.

What is the purpose of the study?

The world has changed enormously since the outbreak of coronavirus disease (COVID-19). In many countries severe asthma physicians had to change how care was delivered to their patients. This may have changed patients' asthma symptoms, emotions or satisfaction with care.

In this study we are going to investigate changes in severe asthma care and the impact on patients. We are sending out surveys to patients with severe asthma and to severe asthma physicians across Europe. Your doctor will not see your individual answers and your answers will be kept strictly confidential. The results of this study will help us work to improve severe asthma care in case of future waves of COVID-19.

What will happen to me if I take part?

After reading this information sheet, please click the "next button" on the main page. This will start the survey. In the first question of the survey we will ask your consent for taking part in this study. The survey will be in your own

language and you will not need help from your asthma physician to complete the survey. After completing the survey you will be asked to submit your answers.

There will be paper surveys available in some countries, this depends on your asthma physician or your internet access. If you complete a paper survey, written and verbal consent is needed. Your data will be kept anonymous.

The survey includes multiple-choice questions, and also a couple of questions on your age, gender and medications for your asthma.

You will not receive any financial compensation for taking part in this survey, but taking part will help provide better asthma care during the COVID-19 pandemic in the future.

Sharing your experience of changes in your asthma care or asthma symptoms during the coronavirus outbreak may be stressful or upsetting. If this happens, you can choose not to share this information or stop answering the survey. You do not have to give a reason for stopping.

Do I have to take part?

This survey is voluntary, you decide if you would like to participate or not. If you decide to take part, you will be asked to give your consent to participate in the first question of the survey. If you want to take part, you can withdraw at any time and without giving a reason. To withdraw simply exit the survey. A decision to withdraw or a decision not to take part will have no effect on your treatment or for your health insurance.

What happens to the collected data?

All information that is collected about you during the course of this study will be kept strictly confidential and anonymised. The data collected for this study via the SurveyMonkey system will be kept in a secure file at the Amsterdam

University Medical Center (AUMC) in Amsterdam (the Netherlands) by the study project leaders. Your personal data (first name, last name, email address) will remain anonymous unless you agree to be contacted about our future studies on COVID-19 in severe asthma.

If you decide to withdraw from the study after having submitted your answers:

- Your data and answers are and remain anonymised and cannot be linked to you.

- As we do not know which data is yours, we will be unable to remove it and we will keep any data and answers that have already been collected.

The results of this study will be presented at conferences and published in scientific journals and on the project website (www.sharp-crc.org). Your name or any other details that may identify you will not be released to the public or used in any publications.

Future studies

We are planning follow-up studies to increase the knowledge on COVID-19 in patients with severe asthma. Topics that we plan to explore are:

- the COVID-19 infection rate in severe asthma patients
- the effects of shielding
- the course of COVID-19 in severe asthma patients
- the effect of asthma medication and other factors on COVID-19 disease course

If you are interested to participate in the follow-up studies please leave your contact details (email address or telephone number) with your physician.

Complaints

If you have any concerns about your participation in the study you have the right to talk about this with your asthma physician or respiratory nurse a who invited you to participate.

Who is organising and funding the research?

The survey is being organised by SHARP (Severe Heterogeneous Asthma Research collaboration, Patient-centred), which is a European Respiratory Society (ERS) Clinical Research Collaboration that is working to improve treatment for patients with severe asthma. SHARP is funded by the ERS.

Contact for further information

Local Chief Investigator: XXX
Address
email

Thank you very much for taking the time to read and consider participating in this survey.